The 2039 A/G FSH receptor gene polymorphism influences glucose metabolism in healthy men

Cannarella, Rossella; Musso, Nicolò; Condorelli, Rosita A.; Musmeci, Marco; Stefani, Stefania; Aversa, Antônio; Vignera, Sandro La; Calogero, Aldo E.

doi:10.1007/s12020-020-02420-3

Cited by 3 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, FSH receptor polymorphism seemed to play an important role in increased Mets risk in women. Cannarella R et al have demonstrated that FSHR gene polymorphism, rs6166, significantly influences glucose metabolism [ 34 ]. Moreover, it was reported that women having activated FSHR polymorphisms also have lower bone mass and higher bone turnover [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

Follicle-Stimulating Hormone Positively Associates with Metabolic Factors in Perimenopausal Women

Zhang

Zhao

et al. 2020

International Journal of Endocrinology

View full text Add to dashboard Cite

Objective. Menopause is associated with the increased risk of metabolic syndrome (MetS) and cardiovascular (CV) disease. Most studies have focused the postmenopausal women and the relationships among estrogen, androgen, and Mets risk. The main aim of the study was to investigate the Mets risk in perimenopausal women and whether the variation of FSH is associated with metabolic factors. Methods. A single-center cross-sectional retrospective analysis including 154 premenopausal women and 124 perimenopausal women was performed. Results. The prevalence of Mets in the perimenopausal group was much higher than the premenopausal group (49.19% vs. 35.71%, p = 0.023 ). The prevalence of central obesity and NAFLD also increased in the perimenopausal group than in the premenopausal group. We grouped the population by FSH tertiles; compared with women in the lowest tertile, women in the highest tertile had higher age, WC, serum TC, LDL-C, AST, ALT, and creatine levels. The prevalence of hypertriglyceridemia, raised BP and Mets also increased in the highest tertile group. Further, we subdivided the perimenopausal women according to FSH tertiles. Compared with perimenopausal women in the lowest tertile, the prevalence of raised BP significantly increased in the highest tertile. Conclusions. The risk of Mets increased in perimenopausal females than in premenopausal women. And a higher FSH level was associated with higher WC, TG, BPs, and the risk of Mets in perimenopausal women. Elevated FSH level appears to be a risk factor of MetS biomarkers in perimenopausal women.

show abstract

Section: Discussionmentioning

confidence: 99%

Follicle-Stimulating Hormone Positively Associates with Metabolic Factors in Perimenopausal Women

Zhang

Zhao

et al. 2020

International Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…A recent study reported that men with the GG genotype of the FSH receptor rs6166 SNP have lower levels of blood glucose than those with the AA genotype and their FSH concentrations were inversely correlated with insulin and insulin resistance. Meanwhile, the FSH receptor rs6166 A/G genotype did not affect glucose metabolism in healthy men ( 26 ). Thus, genotype-specific effects of FSH receptors on muscle mass, muscle strength and function should be explored in the future study.…”

Section: Discussionmentioning

confidence: 94%

Association Between Serum Follicle-Stimulating Hormone and Sarcopenia and Physical Disability Among Older Chinese Men: Evidence From a Cross-Sectional Study

Xu²,

Zhang³

et al. 2022

Front. Med.

View full text Add to dashboard Cite

Background: Sarcopenia is a geriatric syndrome characterized by progressive loss of muscle mass, function and quality and associated with a range of adverse health outcomes including disability. Despite a negative correlation between muscle mass and follicle-stimulating hormone (FSH) levels in postmenopausal women, it is unclear if FSH is associated with sarcopenia and its poor outcomes, especially in older men.Methods: We used cross-sectional data from 360 men aged over 80 who participated in health check-ups to investigate correlations between serum FSH and sarcopenia, individual sarcopenia components, low physical performance (gait speed ≤ 0.8 m/s) and instrumental activities of daily living (IADL) disability. Sarcopenia and severe sarcopenia were diagnosed according to the revised definition of the European Working Group on Sarcopenia in Old People (EWGSOP2).Results: The prevalence of sarcopenia was 17.8% in this population. In binary logistic regression analysis, compared with higher FSH group, lower FSH group showed a significant reduction in the risk of low calf circumference (a surrogate for muscle mass; OR 0.308, 95% CI 0.109–0.868, P = 0.026) after adjusting potential confounders including age, waist circumference, education, exercise, associated biochemical parameters, other sex hormones and high-sensitivity C-reactive protein. The correlation between FSH and low handgrip strength was marginally significant (OR 0.390, 95% CI 0.151–1.005, P = 0.051). No associations were observed between FSH and sarcopenia, severe sarcopenia, and disability in adjusted models.Conclusion: In older men, circulating FSH was not associated with sarcopenia, sarcopenia severity, the majority of its components and adverse health outcome (IADL disability), with the exception of low calf circumference. Further work is needed to better elucidate the association of FSH and low muscle quantity by adopting more accurate measurement method of appendicular skeletal muscle mass such as DXA, CT or MRI.

show abstract

Follicle-Stimulating Hormone and Diabetes in Postmenopausal Women: A Systematic Review and Meta-Analysis

Saei Ghare Naz,

Farhadi-Azar,

Noroozzadeh

et al. 2024

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

Background Today, co-occurrence of hormonal changes during menopause and the risk of cardio-metabolic disorders have been well studied. We aimed to explore the association of circulating levels of follicle-stimulating hormone (FSH) with diabetes (DM) among postmenopausal women. Method In this Systematic review and meta-analysis the search was performed on PubMed, Scopus, Web of sciences, Epistemonikos, and Cochrane library until the September 2023. Risk of bias was assessed by Newcastle-Ottawa Quality Assessment Scale. Pooled estimates of mean differences in FSH levels among diabetic postmenopausal women compared to those without diabetes were performed. Also, the correlation between FSH and fasting blood glucose (FBG)/Insulin/Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) as well as the pooled effect sizes with their 95% confidence intervals (CIs) for risk of DM were calculated. Results In this study, 14 articles, including 7,878 postmenopausal women, met eligibility criteria and were further analyzed. Most of the included studies had a low/moderate risk of bias. Women with DM had significantly lower FSH levels than those without DM (standardized mean difference [95% CI] -0.751, 95% CI-1.129 to -0.372, I2 = 82.46%, n = 1416). The pooled effect size (ES) for diabetes was 0.861 (95% CI: 0.740-1.001; I2 = 80.11%). The pooled risk estimate for DM based on the categorical FSH levels (high versus low) was (HR = 0.550; 95% CI, 0.356 to 0.850, I2 = 0). The significant inverse correlation was found between FSH levels and glycemic parameters [FBG (r= -0.285; 95%CI -0.441 to -0.113; n = 1229), HOMA-IR (r = -0.241; 95%CI -0.378 to -0.0924; n = 1229) and Insulin (r = -0.337; 95%CI -0.434 to -0.232; n = 959)]. There were no statistically significant differences between estradiol levels among diabetic and non-diabetic groups; however the SMD for luteinizing hormone was similar to that reported for FSH. Conclusion The available data indicated an indirect association between FSH levels and glucose disturbances among postmenopausal women; notwithstanding heterogeneity among included studies, and the complexity of various influential factors needs to be considered. Further efforts should be made to clarify the underlying mechanisms.

show abstract

The 2039 A/G FSH receptor gene polymorphism influences glucose metabolism in healthy men

Cited by 3 publications

References 30 publications

Follicle-Stimulating Hormone Positively Associates with Metabolic Factors in Perimenopausal Women

Follicle-Stimulating Hormone Positively Associates with Metabolic Factors in Perimenopausal Women

Association Between Serum Follicle-Stimulating Hormone and Sarcopenia and Physical Disability Among Older Chinese Men: Evidence From a Cross-Sectional Study

Follicle-Stimulating Hormone and Diabetes in Postmenopausal Women: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About